KNSA (Kiniksa Pharmaceuticals International) Moat Score: 5/10 (As of Jul. 01, 2026)


KNSA Kiniksa Pharmaceuticals International PLC KNSA
54 GF Score
Price $63.90
GF Value $48.12
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Moat Score?

Kiniksa Pharmaceuticals International KNSA +0.02% 54 Moat Score is 5 as of Jul. 01, 2026. GuruFocus rates KNSA with a GF Score™ of 54/100 and a GF Value™ of $48.12 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Kiniksa Pharmaceuticals International ranks better than 94.67% on this metric.

Kiniksa Pharmaceuticals International has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Kiniksa Pharmaceuticals International has Narrow Moat: Kiniksa Pharmaceuticals has a solid narrow moat due to its valuable intellectual property and patents in the biotech sector. It benefits from some regulatory barriers and innovation capabilities, but lacks strong market leadership and brand strength.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Kiniksa Pharmaceuticals International might have Narrow Moat - Solid narrow moat.

Kiniksa Pharmaceuticals International  (NAS:KNSA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Kiniksa Pharmaceuticals International Moat Score Related Terms

KNSA vs INDV, AMRX, RGC: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiniksa Pharmaceuticals International Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Moat Score distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals International's Moat Score falls into.


KNSA
54GF Score
Kiniksa Pharmaceuticals International PLC KNSA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Kiniksa Pharmaceuticals International (KNSA) has a Moat Score of 5 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #55 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Kiniksa Pharmaceuticals International's Moat Score too high?
Kiniksa Pharmaceuticals International's current Moat Score is 5. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #55 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Moat Score compare to INDV and AMRX?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #55 out of 1031 companies for Moat Score. This places Kiniksa Pharmaceuticals International in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Kiniksa Pharmaceuticals International's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $48.12, compared to a current price of $63.90 — trading 32.8% above its estimated fair value. The current Moat Score is 5. Kiniksa Pharmaceuticals International's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Moat Score is 5 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of $63.90 is trading 32.8% above its estimated GF Value™ of $48.12. GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.

Key valuation signals for KNSA:

  • Moat Score: 5
  • GF Value™: $48.12 vs. price of $63.90 (32.8% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
54GF Score

Get the complete analysis for KNSA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$63.90
Price
$48.12
GF Value